2017-001765-25
An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Openlabel Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children
Novartis·EU Clinical Trials Register
Study focus
- Disease/Condition
- Atopic Dermatitis
Sponsor & location
- Primary sponsor
- Novartis
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Efficacy: (Primary 1) AD disease control over 36 months
ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2017-001765-25
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2017-001765-25 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis and is currently status unknown. The study focuses on Atopic Dermatitis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.